Related Experiment Video
Updated: Mar 22, 2026
08:54
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Published on: May 19, 2020
8.3K
A Predictive Model of Plasma Lamotrigine Levels.
K Kamei1, T Terao1, Y Katayama1
1Department of Neuropsychiatry, Oita University Faculty of Medicine, Yufu, Japan.
Pharmacopsychiatry
|April 26, 2016
Summary
Predicting lamotrigine levels is crucial for bipolar disorder treatment. A new model incorporating lamotrigine dose and valproate use offers a more accurate way to estimate plasma lamotrigine levels, aiding personalized medicine.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Chemistry
Background:
- Lamotrigine is a widely used mood stabilizer for bipolar disorder.
- Individual pharmacokinetic variations necessitate accurate plasma level prediction.
- Establishing a therapeutic window for lamotrigine is an ongoing challenge.
Purpose of the Study:
- To develop a predictive model for plasma lamotrigine levels.
- To identify key factors influencing lamotrigine concentration.
- To improve the precision of lamotrigine level estimation.
Main Methods:
- Stepwise multiple regression analysis was employed.
- Data from 47 patients (lamotrigine levels, liver/renal function) were used for model formulation.
- Model predictive power was validated using a separate dataset of 25 patients.
Main Results:
- Two predictive models for plasma lamotrigine levels were generated.
- Model 1: Lamotrigine level = 2.308 + 0.019 × dose.
- Model 2 (superior predictive power): Lamotrigine level = 0.08 + 0.024 × dose + 4.088 × valproate (1=yes, 0=no).
Conclusions:
- A more accurate predictive equation for lamotrigine levels has been proposed.
- The model incorporating valproate combination demonstrated enhanced predictive capability.
- This tool can assist in prompt and precise lamotrigine level management.
Related Concept Videos
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
55
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
55
01:15Pharmacodynamic Models: Logarithmic Concentration–Effect Model
60
The log-linear model is a pharmacological framework used to describe the relationship between drug concentration and its effect. This model is particularly relevant when the observed effects range between 20% and 80% of the drug’s maximum effect (Emax), where a near-linear relationship is observed between the log of drug concentration and the measured effect. However, the log-linear model does not predict the maximum possible effect (Emax) or the effect at zero drug concentration,...
60
01:29Therapeutic Drug Monitoring: Affecting Factors
322
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
322
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
56
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
56
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
368
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
368
01:14Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
75
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
75